Male pattern baldness — clinically known as androgenetic alopecia — is the most common form of hair loss in men, affecting approximately 50% of men by age 50 and two-thirds by age 35. Despite how common it is, the biology behind it is frequently misunderstood. Most men know it "runs in families" and involves "hormones" somehow — but the specific mechanism, and what that means for treatment, deserves a clearer explanation.

Because the science has progressed considerably in the past two decades, treatments for male pattern baldness are now more effective than ever — particularly when started early. The window to intervene is real, and understanding the biology is the first step toward acting within it.

What Causes Male Pattern Baldness? The DHT Mechanism

The central player in male pattern baldness is not testosterone itself, but a testosterone derivative called dihydrotestosterone — DHT. Here is how the process works:

An enzyme called 5-alpha reductase (primarily type II) converts testosterone into DHT within the hair follicle. DHT is significantly more potent than testosterone — it binds to androgen receptors with roughly five times the affinity. In genetically susceptible hair follicles (primarily those on the crown and hairline, not the sides and back), this DHT-androgen receptor binding triggers a cascade of changes:

This miniaturization process is gradual — typically unfolding over years or decades — which creates the clinical opportunity for intervention. The follicle is not destroyed; it is suppressed. This is why treatments begun early can often halt or significantly slow progression, and why even men with significant thinning may retain dormant follicles capable of some degree of recovery.

The Genetic Component: It's More Complex Than "Your Mom's Dad"

The folklore that male pattern baldness is inherited entirely from the maternal grandfather reflects a kernel of truth about the androgen receptor gene (AR gene), which is located on the X chromosome — and therefore inherited from the mother. Men who inherit a sensitive variant of the AR gene are more susceptible to DHT's miniaturizing effects.

However, androgenetic alopecia is now understood to be polygenic — influenced by dozens of genetic loci, only one of which is on the X chromosome. A 2017 genome-wide association study identified 63 genetic loci associated with male pattern baldness, explaining only a portion of the hereditary risk. This means baldness can be inherited from either side of the family, and that men with bald fathers and maternal grandfathers face higher risk than previously modeled. If both parents' lineages show significant baldness, the likelihood of developing significant hair loss is substantially higher.

The Norwood Scale: Mapping Progression

The Hamilton-Norwood scale is the standard classification system for male androgenetic alopecia. It describes seven stages of hair loss progression:

Understanding where you fall on this scale is clinically important for two reasons: it helps predict likely future progression without treatment, and it helps determine which interventions are most likely to be effective. Hair restoration — whether pharmacological or surgical — is almost always more successful at earlier Norwood stages.

Finasteride: How It Works and What to Expect

Finasteride is a 5-alpha reductase inhibitor — it works by blocking the enzyme that converts testosterone into DHT. At the standard 1 mg dose used for hair loss, finasteride may reduce scalp DHT levels by approximately 60–70%. This reduction is typically sufficient to slow follicle miniaturization significantly and, in many men, allow some degree of follicle recovery.

Clinical trial data for finasteride is robust:

Finasteride works best on the crown and mid-scalp. It is generally less effective at restoring a significantly receded hairline, though it can slow further recession. Results typically become visible at 6–12 months, with maximum benefit often seen at 18–24 months.

Regarding side effects: sexual side effects including reduced libido, erectile changes, and ejaculatory volume reduction have been reported in clinical trials at rates of approximately 1–2% above placebo. Most side effects resolve with discontinuation. Post-finasteride syndrome — persistent sexual side effects following discontinuation — has been reported by some patients and is an area of ongoing research; however, its prevalence remains debated in the literature. Men considering finasteride should discuss this with their physician and make an informed decision. Learn more on our finasteride page.

Minoxidil: A Different Mechanism, Complementary Benefits

Minoxidil is the other cornerstone of hair loss pharmacotherapy and works through a completely different mechanism than finasteride. Originally developed as an oral antihypertensive, minoxidil's hair growth properties were discovered as a side effect. Applied topically to the scalp (as a 2% or 5% solution or foam), minoxidil:

Minoxidil's clinical evidence is also substantial: studies show approximately 40–60% of men experience meaningful hair regrowth with consistent use. It works most effectively on the crown and top of the scalp. Initial shedding (telogen effluvium) is common in the first 4–8 weeks as follicles shift cycle phases — this is normal and does not indicate the treatment is failing.

Oral minoxidil — at doses of 0.25 mg to 2.5 mg daily — has gained significant clinical attention in recent years as a more systemic and potentially more effective alternative to topical application, with a favorable safety profile at low doses. Discuss this option with your provider. More details are available on our minoxidil page.

Combination Therapy: The Gold Standard

Using finasteride and minoxidil together produces better outcomes than either alone — and this combination is increasingly considered the gold standard for treating androgenetic alopecia. Because the two medications work through entirely different mechanisms (DHT reduction vs. follicle stimulation and cycle prolongation), their effects are complementary and additive.

A 2015 study published in the Dermatologic Surgery journal found that combination therapy produced significantly greater hair count improvements than monotherapy with either agent after 12 months. Clinical photographs consistently show more robust regrowth with combination use. For men willing and able to use both consistently, this approach offers the greatest likelihood of halting progression and achieving visible improvement.

Why Timing Matters: The Earlier, the Better

This cannot be overstated: hair loss treatment is substantially more effective when begun early. Here's why:

Follicles that have undergone mild to moderate miniaturization often retain the ability to produce terminal hair — they are suppressed, not destroyed. Pharmacological intervention during this phase can rescue these follicles and restore meaningful hair density. Follicles that have been dormant for many years, however, typically cannot be reactivated by medical therapy alone.

By the time a man notices "significant" hair loss — the kind that friends and family comment on — he has often already lost 50% or more of the follicles in the affected area. Treatment begun at Norwood stage II or early III has a much higher ceiling for improvement than treatment begun at stage V or VI.

This is particularly relevant for men who notice early temporal recession or crown thinning in their 20s or early 30s. The instinct is often to wait and see. Clinically, "wait and see" means giving the miniaturization process more time to advance — and narrowing the window for effective pharmacological intervention.

What About Other Treatments?

Several additional approaches have evidence supporting their use in combination with or as alternatives to first-line pharmacotherapy:

Low-Level Laser Therapy (LLLT)

FDA-cleared LLLT devices (laser caps and combs) may help stimulate follicle activity and extend the growth phase. Evidence suggests modest benefit — roughly 30–40% report improved hair density. Most clinicians consider this a useful adjunct rather than a primary treatment.

Platelet-Rich Plasma (PRP)

PRP involves drawing a patient's blood, concentrating the platelet-rich fraction, and injecting it into the scalp. Platelets release growth factors (PDGF, VEGF, TGF-beta) that may stimulate follicle activity. Evidence is growing but still heterogeneous — results vary considerably across studies and practitioners. Generally considered an adjunct for men who wish to maximize outcomes beyond pharmacotherapy.

Hair Transplant Surgery

FUE (follicular unit extraction) hair transplants are the most reliable way to restore hair to bald or significantly thinned areas. Follicles from the DHT-resistant donor zone at the sides and back of the scalp are transplanted to recipient areas. Important: surgery should be paired with medical therapy to protect non-transplanted hair from continued miniaturization.

Telehealth Hair Loss Consultation

A telehealth consultation is often the most efficient starting point for men concerned about hair loss. In a single visit, a physician can review your hair loss history, assess your current stage, discuss your goals, and prescribe appropriate pharmacotherapy — often finasteride and minoxidil — without a waiting room or in-person appointment.

Truventa Medical's hair loss program connects you with physicians experienced in androgenetic alopecia who can develop a personalized treatment plan. Early action is the most powerful variable you control.

This article is for informational purposes only. Consult a qualified healthcare provider for personalized medical advice regarding hair loss.